{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:58:40Z","timestamp":1784224720857,"version":"3.55.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>T cells play a central role in the immune response to gastric cancer, and their dysfunction directly contributes to immune escape from the tumor and limits the efficacy of immunotherapy. The immune microenvironment of gastric cancer consists of a wide range of cells and molecules, and this complex and dynamic environment exerts profound inhibitory effects on T cell function. upregulation of PD-1, CTLA-4, and other inhibitory molecules is a key mechanism of T cell depletion, and metabolic reprogramming and chronic antigenic stimulation further weaken the anti-tumor activity of T cells. In recent years, PD-1\/PD-L1 inhibitors have demonstrated some efficacy in gastric cancer, but the problem of drug resistance remains prominent. To address these challenges, combinatorial therapeutic strategies have gradually become the focus of research, especially combining immune checkpoint inhibitors with chemotherapy, radiotherapy, or targeted therapy to enhance the antitumor effect of immunotherapy. This review delves into the molecular mechanisms of T-cell depletion and its impact in gastric cancer immunotherapy, and analyzes the potential application of biomarkers in predicting treatment response. By comprehensively analyzing T-cell depletion and the immune microenvironment in gastric cancer, this paper provides a theoretical basis for the development of future personalized combinatorial therapeutic strategies, with the aim of improving patient prognosis and enhancing the overall therapeutic efficacy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1681539","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:28:41Z","timestamp":1759210121000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Mechanisms and therapeutic strategies to reveal and overcome T-cell dysfunction in gastric cancer: translation from basic research to clinical application"],"prefix":"10.3389","volume":"16","author":[{"given":"Huanyu","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuancheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/CEJ.0000000000000480","article-title":"Gastric cancer: epidemiology, biology, and prevention: a mini review","volume":"28","author":"Lyons","year":"2019","journal-title":"Eur J Cancer Prev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e23918","DOI":"10.1002\/jcla.23918","article-title":"Circular RNA mitochondrial translation optimization 1 correlates with less lymph node metastasis, longer disease-free survival, and higher chemotherapy sensitivity in gastric cancer","volume":"36","author":"Chang","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02896-6","article-title":"Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment","volume":"70","author":"Wu","year":"2021","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731751","article-title":"The CXCL family contributes to immunosuppressive microenvironment in gliomas and assists in gliomas chemotherapy","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.995738","article-title":"Rare metastasis of gastric cancer to the axillary lymph node: A case report","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092266","article-title":"Engineering induced pluripotent stem cells for cancer immunotherapy","volume":"14","author":"Zhou","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-025-00689-6","article-title":"Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies","volume":"14","author":"Wang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205010","article-title":"Resistance mechanisms to CAR T-cell therapy and overcoming strategy in B-cell hematologic Malignancies","volume":"20","author":"Song","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v16.i2.259","article-title":"Biological factors driving colorectal cancer metastasis","volume":"16","author":"An","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12943-024-02169-7","article-title":"Uncovering the predictive and immunomodulatory potential of transient receptor potential melastatin family-related CCNE1 in pan-cancer","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.05.007","article-title":"Future perspectives on engineered T cells for cancer","volume":"10","author":"Posey","year":"2024","journal-title":"Trends Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e25895","DOI":"10.1016\/j.heliyon.2024.e25895","article-title":"Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1\/PD-L1 related immunotherapy methods","volume":"10","author":"Cheng","year":"2024","journal-title":"Heliyon"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.995785","article-title":"Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7158684","DOI":"10.1155\/2022\/7158684","article-title":"The prediction of necroptosis-related lncRNAs in prognosis and anticancer therapy of colorectal cancer","volume":"2022","author":"Xiao","year":"2022","journal-title":"Anal Cell Pathol (Amst)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-2155","article-title":"RNA therapeutics for improving CAR T-cell safety and efficacy","volume":"83","author":"Schaible","year":"2023","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1259461","article-title":"Advances in immunotyping of colorectal cancer","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13059-019-1921-y","article-title":"Distinct epigenetic features of tumor-reactive CD8+ T cells in colorectal cancer patients revealed by genome-wide DNA methylation analysis","volume":"21","author":"Yang","year":"2019","journal-title":"Genome Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000988","article-title":"T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies","volume":"34","author":"Jansen","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.969447","article-title":"Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i40.5582","article-title":"Expression characteristics of peripheral lymphocyte programmed death 1 and FoxP3(+) Tregs in gastric cancer during surgery and chemotherapy","volume":"29","author":"Li","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12920-022-01383-w","article-title":"CD44 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer","volume":"15","author":"Hou","year":"2022","journal-title":"BMC Med Genomics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"101851","DOI":"10.1016\/j.tranon.2023.101851","article-title":"Anti-PD-1\/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations","volume":"40","author":"Chen","year":"2024","journal-title":"Transl Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2018.08.009","article-title":"SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade","volume":"9","author":"Zhao","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.152468","article-title":"Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors","volume":"6","author":"Curnock","year":"2021","journal-title":"JCI Insight"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061353","article-title":"Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression","volume":"13","author":"D\u00edaz-Tejedor","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.929846","article-title":"A genomic instability-related lncRNA model for predicting prognosis and immune checkpoint inhibitor efficacy in breast cancer","volume":"13","author":"Jiao","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203380","article-title":"Immune cell infiltration-associated signature in colon cancer and its prognostic implications","volume":"13","author":"Deng","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112896","article-title":"Metabolic changes in tumor microenvironment: how could they affect \u03b3\u03b4 T cells functions","volume":"10","author":"Corsale","year":"2021","journal-title":"Cells"},{"key":"B31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.coi.2017.04.003","article-title":"Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries","volume":"46","author":"Ho","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e00518","DOI":"10.14309\/ctg.0000000000000518","article-title":"Detecting colorectal adenomas and cancer using volatile organic compounds in exhaled breath: A proof-of-principle study to improve screening","volume":"13","author":"Cheng","year":"2022","journal-title":"Clin Transl Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e2301871","DOI":"10.1002\/advs.202301871","article-title":"SETDB1 methylates MCT1 promoting tumor progression by enhancing the lactate shuttle","volume":"10","author":"She","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12885-020-6629-6","article-title":"Increased PD-1-positive macrophages in the tissue of gastric cancer are closely associated with poor prognosis in gastric cancer patients","volume":"20","author":"Kono","year":"2020","journal-title":"BMC Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac088","article-title":"Biological and molecular factors predicting response to adoptive cell therapies in cancer","volume":"114","author":"Ferrer","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1002\/mco2.265","article-title":"Understanding and targeting resistance mechanisms in cancer","volume":"4","author":"Lei","year":"2023","journal-title":"MedComm"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00669-y","article-title":"Prospects of synergy: local interventions and CAR T cell therapy in solid tumors","volume":"38","author":"Holtermann","year":"2024","journal-title":"BioDrugs"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1915560","DOI":"10.1080\/2162402X.2021.1915560","article-title":"Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients","volume":"10","author":"Jin","year":"2021","journal-title":"Oncoimmunology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c07052","article-title":"Cuproptosis-mediated patterns characterized by distinct tumor microenvironment and predicted the immunotherapy response for gastric cancer","volume":"8","author":"Wang","year":"2023","journal-title":"ACS Omega"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/genes14010124","article-title":"An aggrephagy-related lncRNA signature for the prognosis of pancreatic adenocarcinoma","volume":"14","author":"Huang","year":"2023","journal-title":"Genes"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193103","article-title":"Reprogramming T-cell metabolism for better anti-tumor immunity","volume":"11","author":"Ping","year":"2022","journal-title":"Cells"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910800","article-title":"Ubiquitination in T-cell activation and checkpoint inhibition: new avenues for targeted cancer immunotherapy","volume":"22","author":"Gavali","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0381","article-title":"CD155T\/TIGIT signaling regulates CD8(+) T-cell metabolism and promotes tumor progression in human gastric cancer","volume":"77","author":"He","year":"2017","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3201940","DOI":"10.1155\/2018\/3201940","article-title":"The progress of T cell immunity related to prognosis in gastric cancer","volume":"2018","author":"Wei","year":"2018","journal-title":"BioMed Res Int"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020085","article-title":"Cancer vaccines: antigen selection strategy","volume":"9","author":"Zhao","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e34990","DOI":"10.1097\/MD.0000000000034990","article-title":"Predictive value of tumor mutational burden for PD-1\/PD-L1 inhibitors in NSCLC: A meta-analysis","volume":"102","author":"Li","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12060700","article-title":"A novel classification model for lower-grade glioma patients based on pyroptosis-related genes","volume":"12","author":"Shen","year":"2022","journal-title":"Brain Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-21-0886","article-title":"Pan-cancer HLA gene-mediated tumor immunogenicity and immune evasion","volume":"20","author":"Gong","year":"2022","journal-title":"Mol Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4959","article-title":"The landscape of enhancer RNA identify prognosis-related molecular subtypes in gastric cancer","volume":"12","author":"Yan","year":"2023","journal-title":"Cancer Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1254232","article-title":"Unraveling the role of disulfidptosis-related LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms","volume":"10","author":"Chi","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/cjop.CJOP-D-22-00078","article-title":"Collagen type V alpha 2 promotes the development of gastric cancer via M2 macrophage polarization","volume":"66","author":"Guo","year":"2023","journal-title":"Chin J Physiol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612915","article-title":"Construction and validation of a reliable disulfidptosis-related lncRNAs signature of the subtype, prognostic, and immune landscape in colon cancer","volume":"24","author":"Dong","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70685","article-title":"The key role of COA6 in pancreatic ductal adenocarcinoma: metabolic reprogramming and regulation of the immune microenvironment","volume":"29","author":"Jiang","year":"2025","journal-title":"J Cell Mol Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s12672-025-02617-w","article-title":"Deciphering the role of acetylation-related gene NAT10 in colon cancer progression and immune evasion: implications for overcoming drug resistance","volume":"16","author":"Zhou","year":"2025","journal-title":"Discov Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12061286","article-title":"Recent trends and potential of radiotherapy in the treatment of anaplastic thyroid cancer","volume":"12","author":"Sekihara","year":"2024","journal-title":"Biomedicines"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1758835920967238","DOI":"10.1177\/1758835920967238","article-title":"Hereditary diffuse gastric cancer therapeutic roadmap: current and novel approaches in a nutshell","volume":"12","author":"El Rami","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13073-018-0605-7","article-title":"Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine","volume":"10","author":"Conway","year":"2018","journal-title":"Genome Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2023.60","article-title":"Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1\/PD-L1 treatment","volume":"6","author":"Laubach","year":"2023","journal-title":"Cancer Drug Resist"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e1461","DOI":"10.1002\/ctm2.1461","article-title":"Personalised neoantigen-based therapy in colorectal cancer","volume":"13","author":"Zhu","year":"2023","journal-title":"Clin Transl Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"116532","DOI":"10.1016\/j.biopha.2024.116532","article-title":"Efficient combination of radiotherapy and CAR-T - A systematic review","volume":"174","author":"Szlasa","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.omto.2020.08.009","article-title":"Chimeric antigen receptor T cell therapy targeting ICAM-1 in gastric cancer","volume":"18","author":"Jung","year":"2020","journal-title":"Mol Ther Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.759558","article-title":"Advances in adoptive cell therapy using induced pluripotent stem cell-derived T cells","volume":"12","author":"Netsrithong","year":"2021","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01624","article-title":"Colorectal cancer immunotherapy: options and strategies","volume":"11","author":"Johdi","year":"2020","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e10585","DOI":"10.1002\/btm2.10585","article-title":"Membrane fusogenic nanoparticle-based HLA-peptide-addressing universal T cell receptor-engineered T (HAUL TCR-T) cell therapy in solid tumor","volume":"8","author":"Xu","year":"2023","journal-title":"Bioeng Transl Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.794205","article-title":"Prediction of the drug-drug interaction types with the unified embedding features from drug similarity networks","volume":"12","author":"Yan","year":"2021","journal-title":"Front Pharmacol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-022-01294-4","article-title":"Exploring immunotherapy in colorectal cancer","volume":"15","author":"Weng","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e2305245120","DOI":"10.1073\/pnas.2305245120","article-title":"Tumor cell-derived spermidine is an oncometabolite that suppresses TCR clustering for intratumoral CD8(+) T cell activation","volume":"120","author":"Hibino","year":"2023","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928623","article-title":"Identification of key biomarkers in systemic lupus erythematosus by a multi-cohort analysis","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1038\/s41467-022-33267-z","article-title":"A single arm phase Ib\/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer","volume":"13","author":"Lee","year":"2022","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1003859","article-title":"Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer","volume":"13","author":"Pan","year":"2022","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5534","article-title":"New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)","volume":"63","author":"Wang","year":"2023","journal-title":"Int J Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/psp4.12143","article-title":"Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors","volume":"6","author":"Bajaj","year":"2017","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46080544","article-title":"Effects of heat-induced oxidative stress and astaxanthin on the NF-kB, NFE2L2 and PPAR\u03b1 Transcription factors and cytoprotective capacity in the thymus of broilers","volume":"46","author":"Kuehu","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19123837","article-title":"Targeting adenosine receptor signaling in cancer immunotherapy","volume":"19","author":"Sek","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.fmre.2021.11.032","article-title":"Personalized cancer vaccines from bacteria-derived outer membrane vesicles with antibody-mediated persistent uptake by dendritic cells","volume":"2","author":"Liang","year":"2022","journal-title":"Fundam Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e1543","DOI":"10.1002\/ctm2.1543","article-title":"Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours","volume":"14","author":"Chen","year":"2024","journal-title":"Clin Trans Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"011502","DOI":"10.1063\/5.0073746","article-title":"Engineering CAR T cells for enhanced efficacy and safety","volume":"6","author":"Wu","year":"2022","journal-title":"APL Bioeng"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914660","article-title":"Novel therapeutic targets in cancers","volume":"24","author":"Levantini","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v13.i5.366","article-title":"Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges","volume":"13","author":"Matsuoka","year":"2021","journal-title":"World J Gastrointest Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1681539\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:28:42Z","timestamp":1759210122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1681539\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":82,"alternative-id":["10.3389\/fimmu.2025.1681539"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1681539","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"article-number":"1681539"}}